Dr. John Goethe, director of clinical research at the Burlingame Center for Psychiatric Research at the IOL, is conducting a new trial using a new, non-invasive medical device for the treatment of depression known as low emission NeoSync EEG synchronized transcranial magnetic stimulation (sTMS).
Inclusion criteria for the trial include a diagnosis of Major Depressive Disorder, failure to respond to exactly one medication in the current Major Depressive Episode and age between 22 and 65 years old.
trial consists of five 30-minute treatments per week for six weeks.
In addition, Dr. Goethe
recently made a presentationat a psychopharmacology conference sponsored by the Nevada Psychiatric Association
regarding antipsychotic prescribing practices for patients under age 18.
The study, thought to be the largest of its kind, was undertaken at the Institute of Living
"This is an important issue because these antipsychotic medications are commonly prescribed," said Dr. Goethe
The amount of published data about antipsychotic use in children and adolescents who are inpatients is scant, he
said, and antipsychotics are commonly used for indications that have not been approved by the FDA